Table 4.
N-Deacyl-A40926 (DA40), demannosyl-N-deacylA40926 (DMDA40) and their derivatives 
| LCTA | Code no. | X | Y1 = Y2 | Z1 | Z2 | HIV-1 (CEM) |
FIPV (CRFK) |
SARS-CoV (Vero) |
|||
|---|---|---|---|---|---|---|---|---|---|---|---|
| EC50 (μM) | IC50 (μM) | EC50 (μM) | CC50 (μM) | EC50 (μM) | CC50 (μM) | ||||||
| DA40926 and its derivatives S = Man | |||||||||||
| 519 | 55 | H | OH | H | H | >250 | >500 | >80 | >80 | >80 | >80 |
| 700 | 56 | H | NH(CH2)3N+Me2BnPh-p | H | H | 4.0 ± 1.4 | 32 ± 5 | >50 | 63 ± 3 | >80 | >80 |
| DMDA40926 and its derivatives S = H | |||||||||||
| 599 | 57 | H | OH | H | H | 115 ± 21 | >500 | >80 | >80 | >80 | >80 |
| 604 | 58 | H | NH(CH2)3NMe2 | p-BuOBn | p-BuOBn | 5.0 ± 0.7 | 80 ± 6 | >50 | 53 ± 7 | >80 | >80 |
| 605 | 59 | H | NH(CH2)3NMe2 | H | p-BuBn | 12 ± 3.5 | >250 | >60 | 63 ± 3 | 58 ± 2 | >80 |
| 613 | 60*a | CH2N[CH2CH2]2NBnPh-p | OH | H | p-BuBn | 3.5 | 81 | 4.5 ± 0.4a | 50 ± 0 | 21 ± 7 | >80 |
| 614 | 61a | CH2N[CH2CH2]2NBnPh-p | NH(CH2)3NMe2 | H | p-BuBn | 3.5 ± 2.1 | 212 ± 54 | 5.9 ± 1.5 | 30 ± 9 | 21 ± 5 | >80 |
| 737 | 62*a | CH2N[CH2CH2]2NBnBu-p | OH | H | H | 20 ± 7 | 106 ± 2 | 7.5 ± 1.8 | >80 | 43 ± 6 | >80 |
| 738 | 63 | CH2NH(CH2)3N+C10H21Me2 | OH | H | H | 3.5 | 92 | 23 ± 17 | >80 | >80 | >80 |
| 740 | 64 | CH2NH(CH2)3N+C10H21Me2 | NH(CH2)3NMe2 | H | H | 3.5 ± 0.7 | 92 ± 5 | >50 | 55 ± 2 | 52 ± 21 | >80 |
Antiviral values in italics denotes EC50 values equal or lower than 10 μg/ml. An asterix after the compound code no. indicates a selectivity (CC50/EC50) of >10 for the compound against either FIPV and/or SARS-CoV.